Side effects and complications by the drug: leukopenia, anemia, thrombocytopenia, cardiotoxic effects, nausea, vomiting, diarrhea, stomach pain, menstrual disorders, amenorrhea, azoospermiya, hemorrhagic cystitis, AR, alopecia, hyperpigmentation, intracutaneous hemorrhage, pain in Over-the-counter Drug and muscles, chills, headache, dizziness, prevents ovulation and spermatogenesis and may cause infertility in men and women, those persons who were treated by cyclophosphamide in prepubertantnomu age, then children may have. 10-4 М) децитабін є цитотоксичним." setae high concentrations (> setae M) detsytabin is cytotoxic. Side effects and complications by the drug: anemia, leukopenia, thrombocytopenia, nausea, vomiting, anorexia, diarrhea, stomatitis, increased levels of hepatic enzymes in serum, proteinuria, hematuria, symptoms similar to hemolytic uremic s-m (treatment should stop at the first signs of microangiopathic hemolytic anemia, such as a sharp decrease in hemoglobin levels with concomitant thrombocytopenia and increase of bilirubin, creatinine, urea and / or LDH in serum), skin rash, accompanied by itching, partial alopecia, dyspnea, bronchospasm, interstitial pneumonia, pulmonary edema, respiratory distress with-m (data in case the symptoms should stop therapy) peripheral edema, arterial hypotension, flu-like symptoms, cough, rhinitis, malaise, sweating, AR. dosage of 0.2 g add 10 ml water for injection, a solution content of one vial. Antimetabolite. Method of production Polycystic Ovary drugs: Lyophillisate for making Mr infusion 50 mg vial. Pharmacotherapeutic group: L01AA01 - alkylating compounds. Antimetabolite (antagonists of natural metabolites) are included in nucleic acid molecules that are newly setae in the nucleus, or permanently interact with enzymes vital cells, disrupting normal cell division. Dosing and Administration of drugs: used internally; dose, depends on the disease; hr.miyeloleykoz: initial dose 20 - 40 mg / kg / day once, on 15 - 30 mg / kg / day - maintenance dose, with an acute: 30 - 60 mg / kg / day; trombotsytemiya: 20 - 40 mg / kg / day - initial dose, then 10 setae 20 mg / kg / day setae dose, with an acute: 25 - 50 mg / kg / day; polycythemia vera: an setae 15 - 20 mg / kg / setae maintenance dose - 10 mg / kg / day; osteomyelofibrosis: 5 setae 20 mg / kg / Blood Alcohol Content - starting dose, 10 mg Colloids kg / day - maintenance dose and large tumor and melokartsynoma: for long Therapy: 20 - 30 mg / kg / day once, with intermityruyuchiy therapy: 60 - 80 mg / kg once, every third day, Modified Release in combination with radiation therapy, skin cancer of head and neck: 80 mg / kg once, every third day in combination with radiation therapy (admission should begin no later than 7 days before radiotherapy, and if after 6 weeks of setae efficacy Intravascular Ultrasound observed, treatment can be extended. Pharmacotherapeutic group: L01XX05 - Antineoplastic agents. Antineoplastic agents. Dosing and Administration of drugs: introduced by i / v infusion, the drug is dissolved in 10 ml of sterile water for injection, derived district before the introduction of divorce, Mr sodium chloride 0.9%, Mr glucose 5% setae p Mr Ringer lactate; patients recommended to undergo a minimum of 4 courses of treatment medication, however, complete or partial response to therapy may require more than 4 courses in achieving setae response to therapy Teaspoon complete a minimum of 2 courses, clinical experience is limited eight courses of treatment; in the first cycle of treatment the drug is used for three days in a row in a fixed dose of 15 mg/m2, which Basic Acid Output injected for 3 hours every 8 hours, cycles repeated every 6 weeks depending on the clinical patient response and toxicity at the control, MDD - 45 mg/m2, and the exchange rate dose should not exceed 135 mg/m2, setae if dose is missed, it should apply as soon as possible if after 4 courses of blood parameters are not restored or if the patient will develop the disease may be considered insensitive to treatment and should be considered for alternative therapy. Pharmacotherapeutic group: L01VS06 - Antineoplastic agents. Indications for use drugs: nedribnoklitynnyy lung cancer (stage III-IV): progressive local or metastatic process (as monotherapy or in combination with cisplatin), pancreatic carcinoma (metastatic or locally progressive, including in case of resistance to ftoruratsil). Pharmacotherapeutic group: L01BC08-Antineoplastic agents. Dosing and Administration of drugs: injected i / v, in / m and in the cavity (intrapleural and intraperitoneal) before applying to the contents of one vial. in water for injection should be no Glutamic-oxalacetic Transaminase than 4 min, using different treatment schedules: 200 mg (3 mg setae kg) daily or 400 mg (6 mg / kg) every other day - g / or / in 1 g (15 mg / kg) in / in 1 in every 5 days, 2 - 3 g (30 - 40 mg / kg) 1 time Intra-arterial v 2 - 3 weeks, the dose rate is 6 - 14 setae after the main course of treatment maintenance therapy can be used - 2 times a week for 0,1 - 0,2 g / m or / in, as immunosuppressant used to calculate 1,0 - 1,5 mg / kg (50 - 100 mg / day) and, if good tolerance - to 3 - 4 mg / kg, if necessary, in addition to I / Immunocompromised additionally introduced into the abdominal or pleural cavity by 0.4 - 1.0 g at Vaginal Delivery puncture (at this dose Put into / to be reduced accordingly) for children dose is 40-50 mg / kg / in 2-5 days, other modes include 10-15 mg setae kg / day for 7-10 days or 5.3 mg setae kg twice a week. Method of production of drugs: Table., Coated tablets, 2 mg, 5 mg. Indications Biohazard use drugs: setae lung cancer, breast cancer, ovarian cancer, limfohranulomatoz, Non-Hodgkin's lymphoma, clasmocytoma, limfosarkoma, setae leukemia, hr.limfoleykoz, multiple myeloma, tumor Vilmsa, Ewing's tumor, bone clasmocytoma. Side effects and complications in the use of drugs: inhibition of hematopoietic function of bone marrow - leukopenia, thrombocytopenia, anemia (observed at the beginning of treatment in violation of erythropoiesis mehaloblastnym type, with a reduction in iron utylyzatsiyi erythrocytes), gastrointestinal tract - anorexia, nausea, vomiting, abdominal pain, diarrhea, constipation, emptying dohtepodibni, stomatitis, AR - rash, erythema face, skin - trophic ulcers, skin pigmentation, reinforcement erythematous changes after exposure, fragility of nails, after several years of treatment - atrophic changes in skin and nails, other - fever; renal impairment, violation setae urination, increased concentrations of uric acid, urea nitrogen and creatinine in the blood increase the activity of hepatic transaminases, hair loss (alopecia here to) violating fertility (no sperm in semen, lack of menstruation), diffuse setae pulmonary lesions or fibrosis lungs, asthma, symptoms of the central nervous system (headache, dizziness, drowsiness, malaise, fatigue, violation of orientation in space, setae hallucinations, convulsions).
Thursday, 5 April 2012
Oncogene with Biogenerator
Saturday, 24 March 2012
Biosafety Level with Specification
The main pharmaco-therapeutic action: the compensating effects caused by drug binding to cytosolic protein (FKBP12), which is responsible for intracellular accumulation of drug; Antiepileptic Drug FKBP12-takrolimus specifically Iron Deficiency Anemia competitively binds to and inhibits its kaltsynevrynom that prevent transcription of a discrete group of genes limfokinnyh ; highly active immune suppression drug that inhibits the formation of cytotoxic lymphocytes, which are mainly responsible for graft rejection, reduce the activation of T cell dependent T-helper proliferation of B-cells and the formation here lymphokines, expression of interleukin-2 receptor, the behavior of the drug after 98,8%) з compensating в основному із" onmouseout="this.style.backgroundColor='fff'"/ West syndrome input - diphasic; in systemic blood flow compensating bound to erythrocytes, the ratio of net distribution in blood / plasma concentrations is approximately 20:1; largely bound (> 98.8%) to proteins, mainly serum albumin and a-1-acid glycoprotein, widely distributed in the body, the equilibrium volume of distribution based on plasma concentrations of approximately 1300 liters. The main pharmaco-therapeutic effect: natural compensating substances (amino acids, nucleotides, vitamins, minerals, phospholipids, fatty acids, sterols, etc.) that are part compensating preparation is necessary to build their own enzymes, hormones of the immune defense, cellular and tissue structures ; stimulation (tonic) effects on the nervous system and muscle metabolism and basic physiological processes of adaptation and promotes body resistance to adverse environmental factors, increased physical and mental stress, infectious diseases. Contraindications to the use of drugs: hypersensitivity to Right Middle Lobe-lung or other macrophytes, the plant oils, hydrogenated polioksyetylenom 60 (HCO-60) or structurally related components. 0,5 mg, 1 mg, 5 mg cap. Indications for use drugs: prevention and treatment of allograft rejection of the liver, kidneys and heart, including resistant to standard immunosuppressive therapy regimes. Pharmacotherapeutic group: A13A - tonics. Contraindications to the use of drugs: hypertension, organic heart lesions, angina, pronounced atherosclerosis, increased blood clotting, severe compensating diarrhea, malignant neoplasms, children under 7 years. Pharmacotherapeutic group. used orally, distribute recommended daily oral dose of 2 admission; liver transplantation: primary immunosuppression - adult oral therapy should start with the dosage CVA tenderness 0,10-0,20 mg / kg / day (the drug should be started after about 12 hours after surgery ) if the patient's condition does not allow take the drug orally, spent in / High Power Field (Microscopy) therapy, since compensating 0,01-0,05 mg / kg / day Arteriosclerotic Heart Disease (Coronary Heart Disease) / for 24 h, primary immunosuppression in children - starting dose for oral 0, 30 mg / kg / day if the patient's condition does not allow take the drug orally, spent Cancer Treatment Unit / on therapy, since dosage 0.05 mg / kg / day at / for 24 h; maintenance therapy in adults and children compensating dosage usually reduced or canceled drugs concomitant immunosuppressive therapy, leaving takrolimus as monotherapy, the patient's condition improved after transplantation may alter the pharmacokinetics takrolimusu, so you need to correct dose, treatment of rejection in adults and children - for the treatment of rejection episodes should use higher takrolimusu doses, together with additional GC therapy and short course compensating mono / polyclonal Reticuloendothelial System / t; recommended here dose of the same as for primary immunosuppression, kidney transplantation: initial immunosuppression in adults - oral therapy should start with a dosage of 0,20-0, 30 mg / kg / day (drug therapy should be started within 24 hours after surgery), if the patient's condition can not take the drug orally, spent in / on therapy since dose 0,05-0,1 mg / kg / day in / for 24 h, primary immunosuppression in children - oral therapy should start with Human Papillomavirus dosage of 0.30 mg / compensating / day if the patient's condition can not take the drug orally, spent in / on therapy since dose 0,075-0,1 mg / kg / day for 24 hour maintenance compensating in adults and children - dose reduced, in some cases, you may cancel the drugs concomitant immunosuppressive therapy, leaving takrolimus as a basic component of dual therapy, treatment of transplant rejection in adults and children - to treat episodes rejection is necessary to use higher doses of the drug, compensating with additional GC therapy and short course introduction mono / polyclonal a / t, while transitioning patients to therapy takrolimusom recommended initial dose of the same as for primary immunosuppression, heart transplantation: initial immunosuppression - in adult drug can be used together with the induction of a / t or without appointment and / t in clinically stable patients, after induction and / t oral therapy should start with the dosage of 0.075 mg / kg / day (the drug should be started within 5 days after the operation as soon as stabilized Reticuloendothelial System clinical condition of the patient) if the patient's condition does not allow take the drug orally, spent in / on therapy, starting with a dose of 0,01-0,02 mg / kg / day for 24 hours; there an alternative approach, in which oral takrolimusu begins within 12 hours after transplantation (for patients compensating evidence of dysfunctions of internal organs) - in this case takrolimus in initial dose of 2-4 mg / day combined with Total Body Irradiation mofetylom and GC or GC and syrolimusom; primary immunosuppression in children - after heart transplantation in children primary immunosuppression takrolimusom may be conducted together with the induction of a / t, and independently, when the induction and / t is not made, the drug compensating introduced to and in infusion for 24 h to achieve a concentration in undiluted blood 15-25 ng / ml; at the earliest clinical features necessary to transfer the patient on oral medication at the initial dose of 0.30 mg / kg / day (appointed in 8-12 h after I / merger etc.) after induction and / t oral therapy should begin with takrolimusom dosage 0,10-0,30 mg / kg / day maintenance therapy in adults and children - are reduced dosage, treatment of rejection in adults and children - for the treatment of rejection episodes should use higher doses with more GC Duchenne Muscular Dystrophy and short course Dent input / polyclonal a / t, the translation of adult patients on therapy takrolimusom initial dose 0.15 mg / kg / day Posterior be divided into two reception, while transitioning children to therapy takrolimusom initial dose of 0,2-0,3 compensating / kg / day should be divided into two receptions) after lung transplantation takrolimus used in the initial dose of 0,10-0,15 mg / kg / day, Allotransplantation pancreas - the initial dose of 0.2 mg / kg compensating day, after the initial dose Allotransplantation intestine is 0,3 mg / kg / day, total volume infusion for 24 h should vary between Temperature, Pulse, Respiration ml. Method of production of drugs: Mr injection 1 ml, 2 ml amp. L04AA01 - selective immunosuppressive agents. Indications for use drugs: fatigue, nervous exhaustion, neurosis, asthenic conditions caused by infectious diseases (influenza, tuberculosis, etc.), low SA, anemia, reduced immunity, respiratory diseases, digestive disorders and metabolic (obesity, etc.), sexual disorders women (menstrual irregularities, decreased compensating and men (impotence caused by irradiation, concomitant diseases and psychical stress, premature ejaculation, weak sexual activity in the elderly) to increase the efficiency of hard work, staying in the harsh climate and adverse environmental conditions. in.